One step closer to eradicating yaws
19 February 2015London School of Hygiene & Tropical Medicine London School of Hygiene & Tropical Medicine https://lshtm.ac.uk/themes/custom/lshtm/images/lshtm-logo-black.png
A new study published in the New England Journal of Medicine has demonstrated that the World Health Organization's (WHO) proposed strategy to eradicate the neglected tropical disease yaws, by 2020, could be effective. It showed that one round of mass treatment with a single-dose oral drug called azithromycin, greatly reduced the transmission and prevalence of yaws on Lihir Island in Papua New Guinea.
The results of the study, by researchers at the Barcelona Institute for Global Health (ISGlobal), the London School of Hygiene & Tropical Medicine, along with six other organisations worldwide, provide empirical data to support the Morges yaws eradication strategy proposed by WHO in 2012.
Yaws is a chronic neglected tropical disease which is related to syphilis, but is transmitted by nonsexual skin-to-skin contact. It mainly affects children in poor regions and is caused by a bacteria which affects the skin and bones, causing weeping ulcers and severe bone deformities. This highly contagious infection is prevalent in 12 countries in areas where people have poor sanitation and little access to healthcare services.
In the new study, the research team implemented a mass treatment programme that covered all 28 villages of Lihir Island, an area with a very high burden of yaws infection. Every resident older than two months of age was offered a single oral dose of azithromycin. The overall treatment coverage rate was 83.8% of the estimated population of 16,092 people.
After the initial mass treatment campaign, researchers returned to the villages every six months to screen for cases of active yaws through clinical skin examination of every resident person at the time of the survey. At the end of the study, they found that the prevalence of yaws had fallen from 2.4% before treatment to 0.3% at 12 months. They also found that the percentage of participants with latent yaws (disease carriers) decreased from 18.3% to 6.5%.
Dr Oriol Mitjà, lead author of the paper and researcher at ISGlobal, said: "This study provides empirical data demonstrating that one round of mass treatment significantly reduced the prevalence of disease and transmission in the villages. Although a sustained active surveillance and treatment effort will be necessary to achieve zero yaws cases, our data confirm that the WHO strategy has the potential to eradicate this disease."
Study author David Mabey, Professor of Communicable Diseases at the London School of Hygiene & Tropical Medicine, said: "This is the most important study on Yaws for fifty years. It shows that, if the resources were made available to provide and deliver azithromycin to all communities in which yaws is endemic, the WHO target of eradicating this mutilating and disfiguring disease by 2020 could be achieved.
"We have been using azithromycin for the control and elimination of blinding trachoma for almost 20 years and, thanks to the generous donation of more than 350 million doses by the manufacturer, Pfizer Inc, we have succeeded in eliminating trachoma as a public health problem from seven countries. It is a very safe and effective drug with few side effects."
Azithromycin is a cheap and effective antibiotic that is easy to administer. The generic form used in the new yaws study costs US 0.17 for a 500mg tablet, in doses of up to 2g.
In 2012, a team of ISGlobal researchers led by Oriol Mitjà and Quique Bassat showed, for the first time, that a single oral dose of this antibiotic is enough to cure a person with yaws. On the basis of this discovery and other information, the WHO developed the Morges strategy and set 2020 as the target year for yaws eradication.
The new study is a collaboration between researchers at Lihir Medical Centre (Papua New Guinea, PNG), Barcelona Institute for Global Health (Spain), National Department of Health (PNG), University of Washington (US), University of Queensland (Australia), PNG Institute of Medical Research (PNG), London School of Hygiene & Tropical Medicine (UK), and the World Health Organization (Geneva).
Find out more
- Animation explaining the study - The New England Journal of Medicine
- Oriol Mitjà, Wendy Houinei, Penias Moses, August Kapa, Raymond Paru, Russell Hays, Sheila Lukehart, Charmie Godornes, Sibauk Vivaldo Bieb, Tim Grice, Peter Siba, David Mabey, Sergi Sanz, Pedro L. Alonso, Kingsley Asiedu, Quique Bassat, Mass Treatment with Single-Dose Azithromycin for Yaws, New England Journal of Medicine. DOI: 10.1056/NEJMoa1408586